Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Next Previous
X
Search
Trial Profile

A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 20 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MRG 002 (Primary) ; Trastuzumab emtansine
  • Indications Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
  • Focus Therapeutic Use
  • Sponsors Miracogen

    • Most Recent Events

    • 16 Mar 2023 Planned number of patients changed from 290 to 350.
    • 23 Feb 2023 Protocol amended due to changes in study phase, primary outcome, treatment arm and planned patient number as per ClinicalTrials.gov: US National Institutes of Health record.
    • 23 Feb 2023 Planned number of patients changed from 60 to 290.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top